Filing Details

Accession Number:
0000950170-23-068575
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-12-06 16:30:08
Reporting Period:
2023-12-04
Accepted Time:
2023-12-06 16:30:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1157601 Madrigal Pharmaceuticals Inc. MDGL Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1776196 Joseph Brian Lynch C/O Madrigal Pharmaceuticals, Inc.
200 Barr Harbor Drive, Suite 200
West Conshohocken PA 19428
Svp And General Counsel No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-12-04 800 $73.75 15,801 No 4 M Direct
Common Stock Acquisiton 2023-12-04 1,000 $87.09 16,801 No 4 M Direct
Common Stock Disposition 2023-12-04 800 $215.73 16,001 No 4 S Direct
Common Stock Disposition 2023-12-04 1,000 $221.38 15,001 No 4 S Direct
Common Stock Acquisiton 2023-12-05 1,000 $87.09 16,001 No 4 M Direct
Common Stock Disposition 2023-12-05 1,000 $227.33 15,001 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-12-04 800 $0.00 1,000 $73.75
Common Stock Stock Option (Right to Buy) Disposition 2023-12-04 1,000 $0.00 1,000 $87.09
Common Stock Stock Option (Right to Buy) Disposition 2023-12-05 1,000 $0.00 800 $87.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,200 2032-08-10 No 4 M Direct
44,000 2032-02-22 No 4 M Direct
43,000 2032-02-22 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 530 Indirect In IRA
Footnotes
  1. All shares issued pursuant to the exercise of this option represent 800 shares underlying an overall option award of 25,000 shares. All exercised options had vested. As to the overall option for 25,000 shares, 25% of the shares underlying the option vested on August 10, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.
  2. All shares issued pursuant to the exercise of this option represent 2,000 shares underlying an overall option award of 45,000 shares. All exercised options had vested. As to the overall option for 45,000 shares, 25% of the shares underlying the option vested on February 22, 2023 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.